
Merck Receives Positive EU CHMP Opinion for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Infections Due to Aerobic Gram-Negative Organisms in Adults with Limited Treatment Options
Dateline City: KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada,…










.jpg)










